

Luxembourg, 24/06/2026

Environmental and Social Data Sheet¹

Overview

Project Name:	TECHEU VD SALVIA (BIOTECH ACT)	
Project Number:	2025-0741	
Country:	Netherlands	
Project Description:	The project supports research, development and clinical evaluation of an implantable neurostimulation device used as a treatment for patients suffering from chronic migraine and cluster headache.	
Invest EU sustainability proofing required		yes
E&S Risk categorisation		Low as per paragraph 4.18 of E&S Policy
Project included in Carbon Footprint Exercise ² :		no

Environmental and Social Assessment

Environmental Assessment

The Promoter is a medical technology company and develops neurostimulation devices for patients with chronic migraines that do not respond to medical therapy.

The project concerns investments in research and development activities to be carried out by the Promoter in existing facilities without changing their already authorised scope. The project is not listed under Annex I nor Annex II of the EU EIA Directive 2011/52/EU amended by Directive 2014/52/EU, therefore it is not subject to an EIA procedure.

Climate Assessment

Research and development investment activities, such as those present in this project, are regarded presenting a neutral climate impact.

The project has been assessed for Paris alignment and is considered to be aligned with both low-carbon and resilience goals as per the policies set up in the Climate Bank Roadmap and/or

¹ The information contained in the document reflects the requirement related to the environmental, social and climate information to be provided to Investment Committee as required by the Invest EU Regulation and it represents the equivalent of the information required in the template of the InvestEU sustainability proofing summary

² Only projects that meet the scope of the Carbon Footprint Exercise, as defined in the EIB Carbon Footprint Methodologies, are included, provided estimated emissions exceed the methodology thresholds: 20,000 tonnes CO₂e/year absolute (gross) or 20,000 tonnes CO₂e/year relative (net) – both increases and savings.



Luxembourg, 24/06/2026

associated guidance and other relevant documents (e.g. the Energy Lending Policy). The project concerns RDI activities in eligible sectors.

The Promoter is in scope but screened out of the PATH framework as it does not operate in a high-emitting sector and is not considered as a highly-vulnerable counterpart.

Social Assessment

The Promoter's R&D facilities and practices comply with relevant national and EU regulations and the promoter maintains adequate internal procedures and management practices, especially regarding labour standards and occupational health and safety.

In alignment with these rigorous standards, pre-clinical activities comply with the European Directive 2010/63/EU on the protection of animals used for scientific purposes, where applicable. Likewise, clinical trials are conducted in compliance with Regulation (EU) No. 536/2014, where applicable, and the Promoter adheres to all legal standards for anonymisation and data protection.

Other Environmental and Social Aspects

The Promoter is ISO 13485 certified and maintains a quality management system (QMS) that meets or exceeds the requirements of the EN ISO 13485 standard. If successful, the project is expected to lead to important social benefits, considering the targeted indications and the level of unmet medical need. Through the R&D activities and investments, the Promoter is also expected to sustain its current level of skilled personnel, while contributing to European scientific innovation, hence fostering and nurturing the vital research community.

Conclusions and Recommendations

The Promoter has effective E&S policies and operating procedures in place, which are in line with industry standards.

The project concerns investments in research and development for which no significant impact on the environment is expected.

Sustainability proofing conclusion: The project is carried out in compliance with applicable national and EU environmental and social legislation. Based on the environment, climate and social (ECS) information, the review of the ECS risks and impacts and the management systems in place, the project is deemed to have low residual ECS risks and impacts. No further sustainability proofing is required.

Considering the above, taking into consideration the Environmental, Social and Climate impacts of this RDI project, including the capacity of the promoter and the overall net positive social impact, this project is deemed acceptable for the Bank's financing under environmental and social terms.